Maxona Pharmaceuticals

MAXONA Pharmaceuticals' leadership is committed to therapies for unmet medical needs.

The page lists MAXONA Pharmaceuticals' latest news, upcoming events, and contact information.

MAXONA Pharmaceuticals offers non-addictive therapies for acute and chronic pain.

Maxona Pharmaceuticals' privacy practices cover data collection, cookies, and how visitor information is used and shared.

MAXONA Pharmaceuticals secures a **notice of allowance** from the USPTO for a patent covering the use of **nefopam** in treating **pruritus** (chronic itching). The approval advances the company’s pipeline of novel pain and itch therapies. Nefopam is a centrally acting analgesic with potential applications in dermatological and neuropathic conditions.

Oct 2026PR NewswireNews article

MAXONA Pharmaceuticals secures FDA clearance for its Investigational New Drug (IND) application, advancing **MAX-001** into a **Phase 2 clinical trial** focused on acute pain treatment. The trial marks a key step in evaluating the drug’s safety and efficacy in managing acute pain conditions. MAXONA now proceeds with human testing under FDA oversight.

Jul 2026PR NewswireNews article

MAXONA Pharmaceuticals submits an Investigational New Drug (IND) application to the US FDA for **MAX-001**, its lead compound targeting **acute pain**. The filing marks a critical step toward potential clinical evaluation of the therapy. MAX-001 represents the company’s primary candidate in pain management, aligning with growing demand for novel treatments in this therapeutic area.

Aug 2025Pharmaceutical TechnologyNews article

MAXONA Pharmaceuticals submits an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental therapy, **MAX-001**. The filing marks a key regulatory step toward evaluating the drug’s safety and potential efficacy in clinical trials. MAXONA develops novel treatments targeting neurological disorders.

Aug 2025PR NewswireNews article